Rituximab treatment for dermatitis herpetiformis in the setting of type 1 diabetes mellitus, celiac disease, vitiligo, autoimmune hemolytic anemia, and autoimmune thrombocytopenia

Nguyen, Katarina T.; Gwinn, Courtney; Vary, James C.

doi:10.1016/j.jdcr.2019.12.007

Cited by 3 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another report of mucous membrane pemphigoid treated with rituximab found persistent IgA deposits in the skin and serum IgAsecreting plasmablasts despite elimination of IgG deposits and CD20+ B cells. However, there are also cases of recalcitrant dermatitis herpetiformis, an IgA-mediated disease, successfully managed with rituximab and a negative serum tissue transglutaminase one year after treatment (14,15) . The reason for this discrepancy between disease processes is unclear and additional studies are warranted.…”

Section: Discussionmentioning

confidence: 99%

Rituximab for linear IgA bullous dermatosis

et al. 2022

View full text Add to dashboard Cite

Linear IgA Bullous Dermatosis (LABD) is an idiopathic or drug-induced vesiculobullous disease typically managed with dapsone or colchicine. We report a case of LABD successfully treated with rituximab who was intolerant of first-line therapies and recalcitrant to typical immunosuppressants. The patient was initially started on prednisone and mycophenolate mofetil which resulted in minimal response and disease progression. Improvement was seen after two infusions of rituximab 1000mg at two weeks apart with planned maintenance therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Rituximab for linear IgA bullous dermatosis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This therapeutic strategy may be employed as well together with dapsone to generate a better response, but patients should also keep themselves properly hydrated throughout treatment. [10] Other drugs that can be used are superpotent or potent topical steroids to relieve acute symptoms and reduce local lesions in DH, for example clobetasol propionate, dipropionate, or betamethasone valerate. Another treatment that has been proven to be somewhat useful for localized symptoms is dapsone 5% topical.…”

Section: 3 Treatment Of Dermatitis Herpetiformismentioning

confidence: 99%

“…The therapeutic dose needed for cyclosporine, however, may be detrimental to the patient, rendering it ineffective. [10] Nguyen et al in his case report reported the administration of rituximab as an alternative treatment in DH patients, where several other case reports also indicated that rituximab could assist in achieving clinical and serological remission of DH [10]. Singh et al reported a patient with severe DH who was treated effectively with a combination of tetracycline and nicotinamide.…”

Section: 3 Treatment Of Dermatitis Herpetiformismentioning

confidence: 99%

Dermatitis Herpetiformis: An Update on Diagnosis And Treatment

Hazlianda,

Putri

2024

SCRIPTA SCORE Sci Med J.

View full text Add to dashboard Cite

Introduction: Dermatitis herpetiformis is a relapsing skin disease caused by gluten sensitivity, also known as an extraintestinal manifestation of celiac disease. Methods: This article was made by reviewing 14 articles related to dermatitis herpetiformis which obtained from Pubmed, Science Direct, and Google Scholar. Discussion: Dermatitis herpetiformis is characterized by skin lesions vesicles or exoriated papules intensely itchy or excoriated papules on extensor surfaces, scalp, nuchal area, and buttocks. Dermatitis herpetiformis is primarily diagnosed through direct immunofluorescence of granular IgA deposits. However, modern and recent approaches currently use anti-TG3 antibody levels as the main serological diagnostic marker. Recent studies now confirm strict, long-term gluten free diet as the primary treatment modality. The diet is supplemented with sulfonamides as first line drugs treatment, especially dapsone. Proper diagnosis and management are important to improve the quality of life of the patients. Conclusion: Dermatitis herpetiformis is a skin disease related to hypersensitivity which requires comprehensive approach and treatment. Keyword: Celiac Disease, Dapsone, Dermatitis Herpetiformis, Direct Immunofluorescence, Gluten Free Diet Pendahuluan: Dermatitis herpetiformis, juga dikenal sebagai manifestasi ekstraintestinal penyakit celiac. Metode: Artikel ini disusun dengan meninjau 14 artikel berkaitan dengan dermatitis herpetiformis yang didapatkan pada Pubmed, Science Direct, dan Google Scholar. Pembahasan: Dermatitif herpetiformis adalah penyakit kulit yang ditandai dengan vesikel yang gatal atau papula yang terkelupas. Dermatitis herpetiformis didiagnosis terutama melalui imunofluoresensi langsung deposit IgA granular. Namun, pendekatan modern saat ini menggunakan antibodi anti-TG3 sebagai penanda diagnostik serologis utama. Studi terbaru sekarang mengkonfirmasi diet bebas gluten jangka panjang yang ketat sebagai modalitas pengobatan utama. Diet dilengkapi dengan sulfonamida sebagai pengobatan lini pertama, terutama dapson. Diagnosis dan penatalaksanaan yang tepat penting untuk meningkatkan kualitas hidup pasien. Kesimpulan: Dermatitis herpetiformis adalah penyakit kulit yang berkaitan dengan hipersensitivitas dan membutuhkan pendekatan dan tatalaksana yang komprehensif. Kata Kunci: Dapson, Dermatitis Herpetiformis, Diet Bebas Gluten, Imunofluoresensi Langsung, Penyakit Seliak

show abstract

“…Since the exact pathogenesis of vitiligo remains poorly understood, treatment of vitiligo is indeed a tough challenge. Although some promising pathogenesis-based medications such as tofacitinib and simvastatin were reported with good therapeutic effects, these results were based on case reports or studies with small samples [3, 4]. Therefore, considerable interest is focusing on searching novel characteristic biomarkers and pathways responsible for the depigmentation state so as to provide references for potential targeted therapy with better effect.…”

Section: Introductionmentioning

confidence: 99%

Identification of Candidate Genes and Pathways in Nonsegmental Vitiligo Using Integrated Bioinformatics Methods

Xie

2020

Dermatology

View full text Add to dashboard Cite

Background: Nonsegmental vitiligo (NSV) is an acquired depigmentation disorder of unknown origin. Enormous interests focus on finding novel biomarkers and pathways responsible for NSV. Methods: The gene expression level was obtained by integrating microarray datasets (GSE65127 and GSE75819) from the Gene Expression Omnibus database using the sva R package. Differentially expressed genes (DEGs) between each group were identified by the limma R package. The interaction network was constructed using STRING, and significant modules coupled with hub genes were identified by cytoHubba and molecular complex detection. Pathway analyses were conducted using generally applicable gene set enrichment and further visualized in R environment. Results: A total of 102 DEGs between vitiligo lesional skin and healthy skin, 14 lesion-specific genes, and 29 predisposing genes were identified from the integrated dataset. Except for the anticipated decrease in melanogenesis, three major functional changes were identified, including oxidative phosphorylation, p53, and peroxisome proliferator-activated receptor (PPAR) signaling in lesional skin. PPARG, MUC1, S100A8, and S100A9 were identified as key hub genes involved in the pathogenesis of vitiligo. Besides, upregulation of the T cell receptor signaling pathway was considered to be associated with susceptibility of the skin in NSV patients. Conclusion: Our study reveals several potential pathways and related genes involved in NSV using integrated bioinformatics methods. It might provide references for targeted strategies for NSV.

show abstract

Rituximab treatment for dermatitis herpetiformis in the setting of type 1 diabetes mellitus, celiac disease, vitiligo, autoimmune hemolytic anemia, and autoimmune thrombocytopenia

Cited by 3 publications

References 5 publications

Rituximab for linear IgA bullous dermatosis

Rituximab for linear IgA bullous dermatosis

Dermatitis Herpetiformis: An Update on Diagnosis And Treatment

Identification of Candidate Genes and Pathways in Nonsegmental Vitiligo Using Integrated Bioinformatics Methods

Contact Info

Product

Resources

About